Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLMD 
Galmed Pharmaceuticals Ltd (GLMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: GLMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.63% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.00M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.55 | 52 Weeks Range 1.15 - 13.58 | Updated Date 09/16/2025 |
52 Weeks Range 1.15 - 13.58 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.61 |
Earnings Date
Report Date 2025-08-28 | When Before Market | Estimate -0.83 | Actual -0.63 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.21% | Return on Equity (TTM) -53.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4327362 | Price to Sales(TTM) - |
Enterprise Value -4327362 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.32 | Shares Outstanding 5479230 | Shares Floating 5229603 |
Shares Outstanding 5479230 | Shares Floating 5229603 | ||
Percent Insiders 1.19 | Percent Institutions 1.42 |
Upturn AI SWOT
Galmed Pharmaceuticals Ltd
Company Overview
History and Background
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics for liver diseases. Founded in 2000, it has primarily focused on developing treatments for NASH and other liver conditions. It has undergone several clinical trials and collaborations to advance its pipeline.
Core Business Areas
- NASH Drug Development: Galmed develops and tests therapies for Nonalcoholic Steatohepatitis (NASH), a liver disease with limited treatment options.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Aramchol: Aramchol (formerly arachidyl amido cholanoic acid) is Galmed's investigational drug for NASH. Aramchol failed its Phase 3 trial, and the company is assessing the implications of the trial results. Competitors in the NASH space include Madrigal Pharmaceuticals (MDGL), Viking Therapeutics (VKTX), and others.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and significant competition. Liver disease treatments are a high-growth area due to increasing prevalence of NASH and limited existing therapies.
Positioning
Galmed aimed to position itself as a key player in the NASH treatment market with Aramchol. With the failure of the Phase 3 trial, its positioning is being reassessed.
Total Addressable Market (TAM)
The NASH market is projected to reach tens of billions of dollars. Galmed's positioning is currently weak due to the Phase 3 trial failure.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Prior clinical trial data and research
- Established intellectual property (though its value is now uncertain)
Weaknesses
- Clinical trial setbacks (failed Phase 3 trial)
- Limited financial resources
- Dependence on a single drug candidate
Opportunities
- Potential for partnership or acquisition
- New drug development approaches
- Expanding market for liver disease treatments
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Changes in market dynamics.
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
Competitive Landscape
Galmed's competitive advantage was based on Aramchol. Due to the Phase 3 trial failure, it now lags behind competitors with more advanced pipelines and stronger financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and financing rounds.
Future Projections: Future projections are highly uncertain given the Phase 3 trial failure. Further growth depends on the company's ability to identify and develop new assets.
Recent Initiatives: Galmed is assessing options following the Phase 3 trial results. This may include exploring alternative indications for Aramchol or acquiring new assets.
Summary
Galmed Pharmaceuticals is a company that recently faced a major setback with the failure of its Phase 3 trial for Aramchol, a drug intended to treat NASH. This outcome has severely impacted its market position and financial stability, leading to layoffs and a strategic reassessment. The company's future hinges on its ability to explore new avenues for its existing assets or to identify and develop new therapeutic candidates. While the company has an experienced management team, it faces significant challenges in a highly competitive landscape dominated by companies with stronger pipelines and greater financial resources. It needs to look out for financial funding and develop a new target market to be successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports (where available)
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galmed Pharmaceuticals Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-03-13 | Co-Founder, President, CEO & Chairman Mr. Allen Baharaff | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://galmedpharma.com |
Full time employees 3 | Website https://galmedpharma.com | ||
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.